MyMD Pharmaceuticals, Inc. (MYMD)
NASDAQ (CM) NASDAQ (CM) Primary Summary
MYMD Chart
MyMD Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JHW Jefferson H. West Legacy Investment Solutions LLC | 60 | $35 | $34.8 | - | - |
MyMD Pharmaceuticals, Inc. (MYMD) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
MyMD Pharmaceuticals, Inc. Profile
| - Industry | - Sector | Dr. Christopher C. Chapman Jr., M.D. CEO | NASDAQ (CM) Exchange | 00973E409 CUSIP |
| US Country | 6 Employees | - Last Dividend | 15 Feb 2024 Last Split | 23 Jan 2014 IPO Date |
Overview
MyMD Pharmaceuticals, Inc. is a trailblazing clinical development stage pharmaceutical company, dedicated to innovating therapeutic solutions aimed at the treatment of aging and age-related diseases, autoimmune disorders, and chronic conditions related to pain, anxiety, and sleep disturbances. Founded in 2014, with its headquarters in Baltimore, Maryland, MyMD Pharmaceuticals is at the forefront of developing groundbreaking drugs designed to improve the quality of life for individuals suffering from these conditions, leveraging cutting-edge science to extend healthspan and tackle the root causes of disease. The company's focus on manipulating the immune system and inflammatory processes presents a novel approach to preventing and managing a wide spectrum of diseases associated with aging and immune dysfunction.
Products and Services
MyMD Pharmaceuticals is spearheading the development of two primary therapeutic platforms:
- MYMD-1: A revolutionary clinical stage small molecule drug platform that plays a critical role in regulating the immune system and its pro-inflammatory cytokines. MYMD-1 is engineered to prevent and treat a variety of autoimmune diseases and age-related illnesses by mitigating immune system overactivity and inflammation, hallmarks of these conditions. The drug is currently undergoing a Phase 2 clinical trial, targeting a range of diseases, including sarcopenia (muscle degeneration due to aging), multiple sclerosis, diabetes, inflammatory bowel diseases, rheumatoid arthritis, as well as conditions such as inflammation-related depression and anxiety. The potential of MYMD-1 also extends to addressing COVID-19-associated depression, presenting a broad therapeutic scope.
- Supera-CBD: A synthetic analog of cannabidiol, designed as a novel solution for managing epilepsy, pain, and anxiety/depression. Leveraging the therapeutic benefits of cannabidiol without the legal and regulatory challenges associated with natural cannabis products, Supera-CBD represents an innovative approach to treating these conditions. Its development is a testament to the company's dedication to addressing unmet medical needs with precision and innovation.
